Shalini Subramaniam

Sydney, NSW, Australia

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 16 publications

177Lu-PSMA-617 SPECT/CT for Early Prediction of Overall Survival in Participants with Metastatic Castration-Resistant Prostate Cancer.

177Lu-PSMA-617 SPECT/CT for Early Prediction of Overall Survival in Participants with Metastatic Castration-Resistant Prostate Cancer.

Journal: Radiology
Published: April 28, 2026

Pembrolizumab and Denosumab in Clear-Cell Renal-Cell Carcinoma.

Pembrolizumab and Denosumab in Clear-Cell Renal-Cell Carcinoma.

Journal: Clinical genitourinary cancer
Published: January 16, 2026

Prognostic Value of Interim PSMA-PET Total Tumor Volume for Overall Survival Within ENZA-p, A Randomized Phase 2 Trial of Enzalutamide Versus Enzalutamide Plus [177Lu] Lu-PSMA-617 (ANZUP1901).

Prognostic Value of Interim PSMA-PET Total Tumor Volume for Overall Survival Within ENZA-p, A Randomized Phase 2 Trial of Enzalutamide Versus Enzalutamide Plus [177Lu] Lu-PSMA-617 (ANZUP1901).

Journal: European urology
Published: December 14, 2025

Healthcare professionals' perspectives on the barriers and enablers of cancer clinical trial participation among Arabic-speaking cancer patients in Australia: a qualitative study.

Healthcare professionals' perspectives on the barriers and enablers of cancer clinical trial participation among Arabic-speaking cancer patients in Australia: a qualitative study.

Journal: Trials
Published: November 05, 2025

Curability of metastatic cancer: a survey of medical oncologists.

Curability of metastatic cancer: a survey of medical oncologists.

Journal: JNCI cancer spectrum
Published: September 18, 2025

Prognostic and predictive value of baseline PSMA-PET total tumour volume and SUVmean in metastatic castration-resistant prostate cancer in ENZA-p (ANZUP1901): a substudy from a multicentre, open-label, randomised, phase 2 trial.

Prognostic and predictive value of baseline PSMA-PET total tumour volume and SUVmean in metastatic castration-resistant prostate cancer in ENZA-p (ANZUP1901): a substudy from a multicentre, open-label, randomised, phase 2 trial.

Journal: The Lancet. Oncology
Published: April 26, 2025

Predictive value of early PSMA upregulation for the response to enzalutamide ± 177Lu-PSMA-617 in poor-risk, metastatic, castration-resistant prostate cancer: substudy of the randomized, phase 2 ENZA-p trial.

Predictive value of early PSMA upregulation for the response to enzalutamide ± 177Lu-PSMA-617 in poor-risk, metastatic, castration-resistant prostate cancer: substudy of the randomized, phase 2 ENZA-p trial.

Journal: Nature cancer
Published: March 25, 2025

Overall survival and quality of life with [177Lu]Lu-PSMA-617 plus enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer (ENZA-p): secondary outcomes from a multicentre, open-label, randomised, phase 2 trial.

Overall survival and quality of life with [177Lu]Lu-PSMA-617 plus enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer (ENZA-p): secondary outcomes from a multicentre, open-label, randomised, phase 2 trial.

Journal: The Lancet. Oncology
Published: November 29, 2024

Durvalumab, Tremelimumab, and Platinum Chemotherapy in EGFR Mutation-Positive NSCLC: An Open-Label Phase 2 Trial (ILLUMINATE).

Durvalumab, Tremelimumab, and Platinum Chemotherapy in EGFR Mutation-Positive NSCLC: An Open-Label Phase 2 Trial (ILLUMINATE).

Journal: JTO clinical and research reports
Published: September 18, 2024

[177Lu]Lu-PSMA-617 plus enzalutamide in patients with metastatic castration-resistant prostate cancer (ENZA-p): an open-label, multicentre, randomised, phase 2 trial.

[177Lu]Lu-PSMA-617 plus enzalutamide in patients with metastatic castration-resistant prostate cancer (ENZA-p): an open-label, multicentre, randomised, phase 2 trial.

Journal: The Lancet. Oncology
Published: January 14, 2024

Variations in Patterns of Prescribing Durvalumab in Stage III Lung Cancer: A Survey of Australian Medical Oncologists.

Variations in Patterns of Prescribing Durvalumab in Stage III Lung Cancer: A Survey of Australian Medical Oncologists.

Journal: Oncology
Published: November 08, 2023

Timing of prognostic discussions in people with advanced cancer: a systematic review.

Timing of prognostic discussions in people with advanced cancer: a systematic review.

Journal: Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer
Published: August 07, 2023
Showing 1-12 of 16

Last Updated: 09/26/2026